We’re heading into the home stretch of 2023, which will be marked by one last congress for the year. This week, over 30,000 global clinical, research, industry, and other colleagues are gearing up to descend into San Diego CA for the 65th American Society of Haematology (ASH) Annual Meeting and Exposition.

With over 7,000 extraordinary pieces of research accepted, representing some of the most cutting-edge science in haematology, I see this as an opportunity for passionate clinical colleagues, researchers, innovators, and others to share best practices, collaborate, and move forward overall positive Impacts for patients living with haematological disorders, malignancies, rare diseases, ultra-rare diseases, and more.

Over the past year, we have partnered with several clinical leaders in sickle cell disease (SCD), Waldenstrom’s macroglobulinaemia (WM), myeloproliferative neoplasms (MPN), chronic myeloid leukaemia (CML), multiple myeloma (MM), cold agglutinin disease (CAD), amyloidosis, and more. Through these collaborations, our goal has been to accelerate research, outcomes, access, and patient-centric innovations to support patients living with many of these and others to have a better quality of life, health equity and improved outcomes.

Our work has also seen us partner with leading patient organisations and industry partners to deliver some truly innovative and cutting-edge patient solutions. Notably, we have been focused on developing and using AI as early predictors of deterioration for specific patient groups, with some successful pilot results which will undoubtedly improve care for so many.

In parallel, we have partnered with industry on new and novel approaches which leverage machine learning algorithms and social platforms to capture, understand, and amplify the unmet needs of patients and carers – moving us closer to closing the health equity, access, and outcomes gaps. We are honoured to have been asked to present our work in both spaces as oral presentations and look forward to sharing this with colleagues next week.